Reports
Reports
Sale
The global idiopathic pulmonary fibrosis treatment market size attained a value of USD 3.59 billion in 2023, driven by growing cases of lung diseases, increasing geriatric population, and rising patient awareness, which is likely to propel the demand for idiopathic pulmonary fibrosis treatment. The market is anticipated to grow at a CAGR of 5.8% during the forecast period of 2024-2032 to attain a value of USD 5.96 billion by 2032.
The industry is expected to attain a value of USD 4.3 billion by 2026. The market is being dominated by the North America and European regions.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Idiopathic pulmonary fibrosis (IPF) refers to a severe lung disease. As you breathe in, oxygen travels through tiny airbags in your lungs and into your bloodstream. This flows to the organs from there. IPF causes scar tissue to develop within the lungs, making it hard to breathe. The treatment of this disease can help in slowing down the damage to the lungs.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The idiopathic pulmonary fibrosis treatment market can be broadly categorised based on drug class into:
The EMR report looks into the regional markets for idiopathic pulmonary fibrosis like North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The increased prevalence of idiopathic pulmonary fibrosis (IPF) and the increasing geriatric population are the key drivers of the market. The increase in the number of people smoking cigarettes, leading to a high prevalence of IPF, is also projected to fuel the growth of the market.
The report presents a detailed analysis of the following key players in the global market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.
REPORT FEATURES | DETAILS |
Base Year | 2023 |
Historical Period | 2017-2023 |
Forecast Period | 2024-2032 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Drug Class |
|
Breakup by Marketed Drugs |
|
Breakup by Route of Administration |
|
Breakup by Drug Type |
|
Breakup by Treatment Channel |
|
Breakup by End User |
|
Breakup by Distribution Channel |
|
Breakup by Region |
|
Market Dynamics |
|
Supplier Landscape |
|
Companies Covered |
|
Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Idiopathic Pulmonary Fibrosis Disease Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Idiopathic Pulmonary Fibrosis Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Idiopathic Pulmonary Fibrosis Epidemiology (2016-2031)
5.3 Europe Idiopathic Pulmonary Fibrosis Epidemiology (2016-2031)
5.4 Asia-Pacific Idiopathic Pulmonary Fibrosis Epidemiology (2016-2031)
5.5 Latin America Idiopathic Pulmonary Fibrosis Epidemiology (2016-2031)
5.6 Middle East & Africa Idiopathic Pulmonary Fibrosis Epidemiology (2016-2031)
6 Global Idiopathic Pulmonary Fibrosis Treatment Market Overview
6.1 Global Idiopathic Pulmonary Fibrosis Treatment Market Historical Value (2017-2023)
6.2 Global Idiopathic Pulmonary Fibrosis Treatment Market Forecast Value (2024-2032)
7 Global Idiopathic Pulmonary Fibrosis Treatment Market Landscape
7.1 Idiopathic Pulmonary Fibrosis Treatment: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Idiopathic Pulmonary Fibrosis Treatment: Product Landscape
7.2.1 Analysis by Drug Class
7.2.2 Analysis by Marketed Drugs
7.2.3 Analysis by Route of Administration
7.2.4 Analysis by Drug Type
7.2.5 Analysis by End User
8 Idiopathic Pulmonary Fibrosis Treatment Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Idiopathic Pulmonary Fibrosis Treatment Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Idiopathic Pulmonary Fibrosis Treatment Market Segmentation
11.1 Global Idiopathic Pulmonary Fibrosis Treatment Market by Drug Class
11.1.1 Market Overview
11.1.2 Tyrosine Inhibitors
11.1.3 MAPK Inhibitors
11.1.4 Autotaxin Inhibitors
11.1.5 Others
11.2 Global Idiopathic Pulmonary Fibrosis Treatment Market by Marketed Drugs
11.2.1 Market Overview
11.2.2 Ofev
11.2.3 Esbriet
11.2.4 Pirfenidone
11.2.5 Actimmune
11.2.6 Nintedanib
11.2.7 Interferon Gamma-1b
11.2.8 Others
11.3 Global Idiopathic Pulmonary Fibrosis Treatment Market by Route of Administration
11.3.1 Market Overview
11.3.2 Oral
11.3.2.1 Tablets
11.3.2.2 Capsules
11.3.3 Parentals
11.3.3.1 Intravenous
11.3.3.2 Intramuscular
11.3.4 Others
11.4 Global Idiopathic Pulmonary Fibrosis Treatment Market by Drug Type
11.4.1 Market Overview
11.4.2 Over the Counter
11.4.3 Prescription
11.4.3.1 Branded
11.4.3.2 Generics
11.5 Global Idiopathic Pulmonary Fibrosis Treatment Market by Treatment Channel
11.5.1 Market Overview
11.5.2 Public
11.5.3 Private
11.6 Global Idiopathic Pulmonary Fibrosis Treatment Market by End User
11.6.1 Market Overview
11.6.2 Hospitals
11.6.3 Specialty Clinics
11.6.4 Homecare Settings
11.6.5 Others
11.7 Global Idiopathic Pulmonary Fibrosis Treatment Market by Distribution Channel
11.7.1 Market Overview
11.7.2 Hospital Pharmacy
11.7.3 Retail Pharmacy
11.7.4 Online Pharmacy
11.7.5 Others
11.8 Global Idiopathic Pulmonary Fibrosis Treatment Market by Region
11.8.1 Market Overview
11.8.2 North America
11.8.3 Europe
11.8.4 Asia Pacific
11.8.5 Latin America
11.8.6 Middle East and Africa
12 North America Idiopathic Pulmonary Fibrosis Treatment Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Idiopathic Pulmonary Fibrosis Treatment Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Idiopathic Pulmonary Fibrosis Treatment Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Idiopathic Pulmonary Fibrosis Treatment Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Idiopathic Pulmonary Fibrosis Treatment Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 Boehringer Ingelheim International GmbH.
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 AstraZeneca
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 F. Hoffmann-La Roche Ltd.
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 Trevi Therapeutics
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 FibroGen,Inc.
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 TORAY INDUSTRIES, INC.
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 Pfizer Inc.
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 Johnson & Johnson Services, Inc.
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 Asahi Kasei Corporation
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 Galapagos NV
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
23.11 ZAMBON COMPANY S.P.A.
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Mergers and Acquisitions
23.11.5 Certifications
23.12 Novartis AG
23.12.1 Financial Analysis
23.12.2 Product Portfolio
23.12.3 Demographic Reach and Achievements
23.12.4 Mergers and Acquisitions
23.12.5 Certifications
23.13 Neopharm Group
23.13.1 Financial Analysis
23.13.2 Product Portfolio
23.13.3 Demographic Reach and Achievements
23.13.4 Mergers and Acquisitions
23.13.5 Certifications
23.14 Galecto Biotech
23.14.1 Financial Analysis
23.14.2 Product Portfolio
23.14.3 Demographic Reach and Achievements
23.14.4 Mergers and Acquisitions
23.14.5 Certifications
23.15 Kadmon Holding, Inc.
23.15.1 Financial Analysis
23.15.2 Product Portfolio
23.15.3 Demographic Reach and Achievements
23.15.4 Mergers and Acquisitions
23.15.5 Certifications
23.16 Promedior, Inc.
23.16.1 Financial Analysis
23.16.2 Product Portfolio
23.16.3 Demographic Reach and Achievements
23.16.4 Mergers and Acquisitions
23.16.5 Certifications
23.17 Merck & Co.,Inc.
23.17.1 Financial Analysis
23.17.2 Product Portfolio
23.17.3 Demographic Reach and Achievements
23.17.4 Mergers and Acquisitions
23.17.5 Certifications
23.18 Sanofi
23.18.1 Financial Analysis
23.18.2 Product Portfolio
23.18.3 Demographic Reach and Achievements
23.18.4 Mergers and Acquisitions
23.18.5 Certifications
23.19 Bristol-Myers Squibb Company
23.19.1 Financial Analysis
23.19.2 Product Portfolio
23.19.3 Demographic Reach and Achievements
23.19.4 Mergers and Acquisitions
23.19.5 Certifications
23.20 GlaxoSmithKline plc.
23.20.1 Financial Analysis
23.20.2 Product Portfolio
23.20.3 Demographic Reach and Achievements
23.20.4 Mergers and Acquisitions
23.20.5 Certifications
24 Idiopathic Pulmonary Fibrosis Treatment Market- Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
In 2023, the global market for idiopathic pulmonary fibrosis treatment reached a value of USD 3.59 billion.
The market is anticipated to grow at a CAGR of 5.8% during the forecast period of 2024-2032 to reach a value of USD 5.96 billion by 2032.
The major drivers of the market include the growing prevalence of lung conditions, increasing geriatric population, and rising patient awareness which is likely to propel the demand for idiopathic pulmonary fibrosis treatment.
The increasing number of smokers, which is leading to a rise in prevalence of IPF (idiopathic pulmonary fibrosis) and pollution-triggered lung conditions are expected to be key trends guiding the growth of the market.
The major regions in the market are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
Pirfenidone and nintedanib are the different drug-classes in the global idiopathic pulmonary fibrosis treatment market.
The major players in the market are Boehringer Ingelheim International GmbH., Merck & Co., Inc., Cipla Inc., and F. Hoffmann-La Roche Ag, among others.
Mini Report
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.